SCHEMBL3012912

SCHEMBL3012912

CCCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
CTSS P25774 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPK1 P28482 2/20 0.43
LMNA P02545 1/20 0.43
KCNQ1 P51787 1/20 0.42
KDM1A O60341 1/20 0.42
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
LTA4H P09960 1/20 0.40
SMN1; SMN2 Q16637 6/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
ALDH1A1 P00352 2/20 0.39
RAF1 P04049 1/20 0.39
BRAF P15056 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018292 0.93 AR (0.48) ARNPC1RAB9ACTSSKMT2A
SCHEMBL3016569 0.89 MAPK1 (0.46) ARNPC1RAB9AKMT2AMEN1
SCHEMBL3019382 0.89 SMN1; SMN2 (0.51) ARNPC1RAB9ACTSSKMT2A
SCHEMBL3013248 0.88 CTSS (0.44) ARNPC1RAB9ACTSSLMNA
SCHEMBL3017305 0.88 AR (0.56) ARNPC1RAB9ACTSSKMT2A
SCHEMBL3016854 0.87 KCNQ1 (0.47) ARNPC1RAB9ACTSSKMT2A
SCHEMBL3015600 0.87 SMN1; SMN2 (0.48) NPC1RAB9AKMT2AMEN1MAPK1
SCHEMBL3009647 0.87 KMT2A (0.45) NPC1RAB9AKMT2AMEN1MAPK1
SCHEMBL3009367 0.87 KDM1A (0.56) ARNPC1RAB9ACTSSKMT2A
SCHEMBL3016528 0.86 KCNQ1 (0.56) ARNPC1RAB9ACTSSMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.